afamitresgene autoleucel
afamitresgene autoleucel is listed in the FDA National Drug Code directory with 4 NDC codes, marketed under brand name including TECELRA. Available dosage form: injection, suspension.
Drug details
- Generic Name
- afamitresgene autoleucel
- Brand Names
- TECELRA
- Application Number
- BLA125789
- Sponsor
- USWM, LLC
- NDC Codes
- 4
- Dosage Forms
- INJECTION, SUSPENSION
- Routes
- INTRAVENOUS
- Active Ingredients
- AFAMITRESGENE AUTOLEUCEL
Indications and Usage
1 INDICATIONS AND USAGE TECELRA is indicated for the treatment of adults and pediatric patients 12 years of age and older with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices. TECELRA is a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adults and pediatric patients 12 years of age and older with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices.